Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 19 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.92 Insider Own24.47% Shs Outstand22.05M Perf Week-13.65%
Market Cap68.79M Forward P/E- EPS next Y-1.59 Insider Trans0.00% Shs Float16.76M Perf Month-17.55%
Income-29.49M PEG- EPS next Q-0.40 Inst Own7.97% Short Float5.79% Perf Quarter-21.32%
Sales0.00M P/S- EPS this Y20.37% Inst Trans-0.21% Short Ratio0.98 Perf Half Y-47.01%
Book/sh1.21 P/B2.55 EPS next Y-4.79% ROA-60.38% Short Interest0.97M Perf Year31.91%
Cash/sh1.77 P/C1.75 EPS next 5Y- ROE-131.42% 52W Range0.17 - 9.77 Perf YTD-29.55%
Dividend Est.- P/FCF- EPS past 5Y62.66% ROI-69.90% 52W High-68.27% Beta-1.58
Dividend TTM- Quick Ratio4.29 Sales past 5Y0.00% Gross Margin- 52W Low1723.53% ATR (14)0.39
Dividend Ex-Date- Current Ratio4.29 EPS Y/Y TTM45.09% Oper. Margin0.00% RSI (14)38.30 Volatility6.62% 11.89%
Employees17 Debt/Eq0.77 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price18.60
Option/ShortYes / Yes LT Debt/Eq0.58 EPS Q/Q59.80% Payout- Rel Volume0.39 Prev Close3.17
Sales Surprise- EPS Surprise1.86% Sales Q/Q- EarningsMar 19 AMC Avg Volume986.00K Price3.10
SMA20-20.66% SMA50-18.64% SMA2009.22% Trades Volume383,969 Change-2.21%
Date Action Analyst Rating Change Price Target Change
Mar-14-24Initiated Scotiabank Sector Outperform $13
Feb-08-24Initiated Jefferies Buy $15
Apr-09-24 08:00AM
Apr-04-24 08:00AM
Mar-19-24 09:53PM
Mar-12-24 08:00AM
04:30PM Loading…
Mar-05-24 04:30PM
Feb-26-24 08:00AM
Feb-02-24 04:30PM
Jan-05-24 04:05PM
Dec-01-23 04:15PM
Nov-20-23 08:00AM
Nov-08-23 05:17PM
Oct-12-23 08:25AM
Oct-11-23 04:29PM
08:00AM Loading…
Oct-10-23 04:05PM
Sep-19-23 08:00AM
Sep-05-23 08:00AM
Aug-10-23 04:13PM
Jul-19-23 08:00AM
May-31-23 04:05PM
May-25-23 05:00PM
May-19-23 04:05PM
May-10-23 04:15PM
Apr-28-23 08:00AM
Apr-27-23 04:58PM
Apr-26-23 06:41PM
Apr-17-23 09:00AM
05:26PM Loading…
Mar-22-23 05:26PM
Mar-15-23 04:05PM
Mar-14-23 04:30PM
Nov-22-22 04:05PM
Nov-10-22 09:00AM
Nov-08-22 08:00AM
Nov-02-22 08:00AM
Oct-06-22 08:00AM
Sep-07-22 08:00AM
Aug-15-22 08:00AM
Jul-07-22 08:00AM
Jun-09-22 08:00AM
Jun-06-22 04:05PM
May-26-22 04:57PM
May-13-22 08:00AM
Apr-27-22 10:01AM
Apr-08-22 01:00PM
Mar-29-22 04:00PM
Mar-10-22 08:00AM
Mar-08-22 04:30PM
Feb-09-22 08:00AM
Nov-18-21 08:00AM
Nov-12-21 07:00AM
Nov-10-21 04:05PM
Nov-09-21 08:00AM
Nov-08-21 08:00AM
Oct-01-21 08:00AM
Sep-20-21 08:00AM
Sep-13-21 08:00AM
Sep-09-21 04:01PM
Aug-12-21 04:01PM
Aug-09-21 08:00AM
Jul-09-21 08:00AM
Jul-01-21 04:00PM
Tempest Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development and discovery of small molecule drugs for the treatment of cancer. The company was founded in 2011 and is headquartered in Brisbane, CA.